Chest
Volume 132, Issue 2, August 2007, Pages 365-367
Journal home page for Chest

Editorials
Pulmonary Hypertension: From an Orphan Disease to a Public Health Problem

https://doi.org/10.1378/chest.07-0903Get rights and content

References (12)

There are more references available in the full text version of this article.

Cited by (41)

  • Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil

    2019, IJC Heart and Vasculature
    Citation Excerpt :

    Predictive models have been developed and validated in idiopathic, hereditary, and anorexigen-associated PAH, but their usefulness in estimating the survival of patients with World Health Organization (WHO) group I PAH of all etiologies is unclear [7]. Schistosomiasis may be the most prevalent cause of PAH worldwide due to its global distribution and, until recently, its underestimated morbidity [8–10]. Recognized by WHO as a neglected disease, schistosomiasis is endemic in many developing countries, where poverty and poor basic sanitation result in the population coming in to contact with contaminated water during their daily activities.

  • Heritable and idiopathic forms of pulmonary arterial hypertension

    2019, Emery and Rimoin's Principles and Practice of Medical Genetics and Genomics: Cardiovascular, Respiratory, and Gastrointestinal Disorders
  • Heritable and Idiopathic Forms of Pulmonary Arterial Hypertension

    2013, Emery and Rimoin's Principles and Practice of Medical Genetics
View all citing articles on Scopus

Dr. Humbert is Professor, Centre National de Référence sur l'Hypertension Artérielle Pulmonaire, Hôpital Antoine-Béclère, Université Paris-Sud, Assistance Publique - Hôpitaux de Paris. Dr. Khaltaev is Professor, World Health Organization. Dr. Bousquet is Professor, Clinique des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Université de Montpellier. Dr. Souza is Professor, Pulmonary Hypertension Unit, Pulmonary Department, University of Sao Paulo.

Drs. Humbert and Souza have relationships with drug companies including Actelion, Encysive, GlaxoSmithKline, Schering, Pfizer, and United Therapeutics. In addition to being investigators in trials involving these companies, relationships include consultancy services and membership of scientific advisory boards. Drs. Khaltaev and Bousquet have no conflicts of interest to disclose.

View full text